PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.31%
Revenue growth at 50-75% of MRVL's 25.36%. Martin Whitman would worry about competitiveness or product relevance.
149.98%
Gross profit growth above 1.5x MRVL's 30.89%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
197.95%
EBIT growth 1.25-1.5x MRVL's 151.75%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
197.95%
Operating income growth 1.25-1.5x MRVL's 151.75%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
202.16%
Net income growth at 75-90% of MRVL's 244.65%. Bill Ackman would press for improvements to catch or surpass competitor performance.
204.17%
EPS growth at 75-90% of MRVL's 255.56%. Bill Ackman would push for improved profitability or share repurchases to catch up.
200.00%
Diluted EPS growth at 75-90% of MRVL's 244.44%. Bill Ackman would expect further improvements in net income or share count reduction.
0.85%
Share count expansion well above MRVL's 0.44%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.08%
Diluted share count expanding well above MRVL's 1.79%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
4.59%
OCF growth under 50% of MRVL's 11.63%. Michael Burry might suspect questionable revenue recognition or rising costs.
6.18%
FCF growth 50-75% of MRVL's 11.74%. Martin Whitman would see if structural disadvantages exist in generating free cash.
496.50%
10Y revenue/share CAGR under 50% of MRVL's 1032.69%. Michael Burry would suspect a lasting competitive disadvantage.
58.28%
5Y revenue/share CAGR under 50% of MRVL's 119.84%. Michael Burry would suspect a significant competitive gap or product weakness.
5.57%
3Y revenue/share CAGR under 50% of MRVL's 45.35%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
762.18%
10Y OCF/share CAGR under 50% of MRVL's 2600.04%. Michael Burry would worry about a persistent underperformance in cash creation.
29321.27%
5Y OCF/share CAGR above 1.5x MRVL's 143.91%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-53.15%
Negative 3Y OCF/share CAGR while MRVL stands at 45.83%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
550.14%
Below 50% of MRVL's 5626.55%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
275.60%
5Y net income/share CAGR similar to MRVL's 302.02%. Walter Schloss might see both on parallel mid-term trajectories.
-3.13%
Negative 3Y CAGR while MRVL is 3040.51%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1477.85%
10Y equity/share CAGR in line with MRVL's 1411.61%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
97.57%
5Y equity/share CAGR above 1.5x MRVL's 49.24%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
25.94%
3Y equity/share CAGR above 1.5x MRVL's 16.75%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.03%
AR growth well above MRVL's 20.05%. Michael Burry fears inflated revenue or higher default risk in the near future.
-0.56%
Inventory is declining while MRVL stands at 13.16%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.01%
Similar asset growth to MRVL's 5.30%. Walter Schloss finds parallel expansions or investment rates.
6.93%
1.25-1.5x MRVL's 6.00%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-1.20%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
2.64%
R&D dropping or stable vs. MRVL's 10.49%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
16.24%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.